228 related articles for article (PubMed ID: 35116995)
1. Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Wang F; Liu X; Bartholdy BA; Cheng H; Halmos B
Transl Cancer Res; 2019 Oct; 8(6):2425-2438. PubMed ID: 35116995
[TBL] [Abstract][Full Text] [Related]
2. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
Yang YM; Jang Y; Lee SH; Kang B; Lim SM
Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
[TBL] [Abstract][Full Text] [Related]
3. Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
Sun Q; Lu Z; Zhang Y; Xue D; Xia H; She J; Li F
Cells; 2022 Jun; 11(13):. PubMed ID: 35805163
[TBL] [Abstract][Full Text] [Related]
4. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
6.
Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
8. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.
Jimbo T; Hatanaka M; Komatsu T; Taira T; Kumazawa K; Maeda N; Suzuki T; Ota M; Haginoya N; Isoyama T; Fujiwara K
Oncotarget; 2019 Aug; 10(50):5152-5167. PubMed ID: 31497246
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of newly discovered DNA aptamers targeting AXL in a lung cancer cell with acquired resistance to Erlotinib.
Hwang JA; Hur JY; Kim Y; Im JH; Jin SH; Ryu SH; Choi CM
Transl Cancer Res; 2021 Feb; 10(2):1025-1033. PubMed ID: 35116429
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
12. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
Park K; Chang GC; Curigliano G; Lim WT; Soo RA; Molina-Vila MA; Cattan V; Darville H; Gandossi E; Smutna V; Sudey I; Viteri S
Lung Cancer; 2021 May; 155():127-135. PubMed ID: 33798902
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
Yu T; Xia Q; Gong T; Wang J; Zhong D
Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
[TBL] [Abstract][Full Text] [Related]
15. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
Wang TH; Wu CC; Huang KY; Leu YL; Yang SC; Chen CL; Chen CY
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396393
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors.
Nakamura R; Fujii H; Yamada T; Matsui Y; Yaoi T; Honda M; Tanaka N; Miyagawa-Hayashino A; Yoshimura A; Morimoto K; Iwasaku M; Tokuda S; Kim YH; Konishi E; Itoh K; Takayama K
JTO Clin Res Rep; 2023 Jun; 4(6):100525. PubMed ID: 37426308
[TBL] [Abstract][Full Text] [Related]
17.
He Z; Gong F; Liao J; Wang Q; Su Y; Chen C; Lin J; Lin RJ
Transl Cancer Res; 2020 Apr; 9(4):2542-2555. PubMed ID: 35117614
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
